Does excess thyroid hormone exposure increase atrial fibrillation and fracture risk in older adults?

Excess thyroid hormone exposure—whether endogenous or during replacement therapy—is clinically important in older adults because risk rises as TSH becomes more suppressed, particularly below 0.1 mIU/L.

Cardiovascular evidence

• Prospective pooled cohorts found subclinical hyperthyroidism associated with incident atrial fibrillation (AF): HR 1.68 (95% CI 1.16–2.43) versus euthyroidism. Risk was greatest with TSH <0.1 mIU/L (HR 2.54, 1.08–5.99), compared with TSH 0.10–0.44 mIU/L (HR 1.63, 1.10–2.41).
• A meta-analysis similarly reported increased incident AF (RR 1.99, 95% CI 1.43–2.77). In levothyroxine-treated patients, the highest free-T4 quartile was associated with AF (HR 1.22, 1.03–1.44), with most events among people aged ≥65.

Skeletal evidence

• In six prospective cohorts (median age 72), subclinical hyperthyroidism was associated with additional annual femoral-neck bone loss of −0.18% (95% CI −0.34 to −0.02); loss was more pronounced at TSH <0.10 mIU/L.
• A 13-cohort individual-participant meta-analysis (70,298 participants; median age 64) found increased hip-fracture risk (HR 1.36, 1.13–1.64), rising to HR 1.61 (1.21–2.15) with TSH <0.10 mIU/L. Endogenous subclinical hyperthyroidism also predicted any fracture (HR 1.42).
• Among levothyroxine users aged ≥70, higher prescribed daily doses (44–93 µg and >93 µg versus <44 µg) were dose-dependently associated with fracture, though thyroid tests were unavailable.

Mechanistic and clinical implications

• Suppressed TSH is a practical biomarker of excessive thyroid-hormone effect; greater suppression tracks with both arrhythmic and skeletal risk.
• ATA guidance advises avoiding thyroid-hormone overtreatment in older adults, especially TSH <0.1 mIU/L; for those over 70–80 receiving levothyroxine, a TSH target around 4–6 mIU/L may be appropriate.

Bottom line

• The claim is strongly supported: in older adults, excess thyroid hormone exposure is associated with higher AF, bone-loss, and fracture risk, warranting conservative levothyroxine dosing and periodic thyroid-function monitoring.